{
    "title": "Medication Therapy Management Empowerment Act of 2013",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Medication Therapy Management \nEmpowerment Act of 2013''.\n\nSEC. 2. IMPROVED ACCESS TO MEDICATION THERAPY MANAGEMENT UNDER PART D \n              OF THE MEDICARE PROGRAM.\n\n    Section 1860D-4(c)(2) of the Social Security Act (42 U.S.C. 1395w-\n104(c)(2)) is amended--\n            (1) in subparagraph (A)(ii)(I), by striking ``have'' and \n        inserting ``subject to subparagraph (H), have''; and\n            (2) by adding at the end the following new subparagraph:\n                    ``(H) Expansion of definition of targeted \n                beneficiary the expansion reduces spending.--\n                            ``(i) CMS actuary report.--Not later than \n                        January 1, 2014, the Chief Actuary of the \n                        Centers for Medicare & Medicaid Services (in \n                        this subparagraph referred to as the `Chief \n                        Actuary') shall submit to the Secretary and to \n                        Congress a report on whether or not the \n                        expansion described in clause (ii) would, if \n                        implemented, reduce expenditures under this \n                        title. If the Chief Actuary determines that \n                        such expansion would reduce spending under this \n                        title, such report shall include a \n                        certification of such determination.\n                            ``(ii) Expansion described.--The expansion \n                        described in this clause is an expansion of the \n                        definition of targeted beneficiary under \n                        subparagraph (A)(ii) by applying subclause (I) \n                        of such subparagraph as if the following were \n                        inserted before the semicolon at the end: `or a \n                        single chronic disease that accounts for high \n                        spending under this title, including diabetes, \n                        hypertension, heart failure, dyslipidemia, \n                        respiratory disease (such as asthma, chronic \n                        obstructive pulmonary disease, or chronic lung \n                        disorders), bone disease-arthritis (such as \n                        osteoporosis or osteoarthritis), rheumatoid \n                        arthritis, and mental health (such as \n                        depression, schizophrenia, or bipolar \n                        disorder)'.\n                            ``(iii) Application if the chief actuary \n                        determines that the expansion reduces \n                        spending.--If the report under clause (i) \n                        contains the certification described in such \n                        clause, the following rules shall apply:\n                                    ``(I) Implementation of \n                                expansion.--Subject to subclause (III), \n                                effective with respect to plan years \n                                beginning on or after January 1, 2015, \n                                subparagraph (A)(ii)(I) shall be \n                                applied to include the expansion \n                                described in clause (ii).\n                                    ``(II) Updated cms actuary report \n                                based on implementation.--Not later \n                                than March 1, 2020, the Chief Actuary \n                                shall submit to the Secretary and to \n                                Congress a report on the implementation \n                                of the expansion under subclause (I). \n                                Such report shall include an analysis \n                                of whether or not such expansion \n                                reduces spending under this title.\n                                    ``(III) Authority to terminate \n                                expansion if the expansion does not \n                                reduce spending.--If the Chief Actuary \n                                determines in the report under \n                                subclause (II) that the expansion does \n                                not reduce spending under this title, \n                                the Secretary may, effective with \n                                respect to plan years beginning on or \n                                after January 1, 2021, apply \n                                subparagraph (A)(ii)(I) as if this \n                                subparagraph had never been enacted. In \n                                making the determination under the \n                                preceding sentence, the Secretary shall \n                                take into account whether such \n                                expansion improves the quality of care \n                                furnished to, and the health outcomes \n                                of, individuals eligible for services \n                                under a medication therapy management \n                                program by reason of such expansion.''."
}